Haixi New Drug: HX9428 has received Fast Track designation from the U.S. FDA for the treatment of nAMD.

Haisi New Drug Announcement: The company's independently developed innovative drug HX9428 has received Fast Track designation from the U.S. FDA for the treatment of neovascular age-related macular degeneration. This designation will facilitate closer communication between the company and the FDA regarding clinical development, advancing the global clinical development process. Currently, HX9428 has successfully completed Phase I clinical trials in China and is conducting Phase II trials; it has also received FDA approval to initiate Phase II clinical trials in the United States.